Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2023

Open Access 01-12-2023 | Arterial Diseases | Research

The triglyceride-glucose index predicts 1-year major adverse cardiovascular events in end-stage renal disease patients with coronary artery disease

Authors: Enmin Xie, Zixiang Ye, Yaxin Wu, Xuecheng Zhao, Yike Li, Nan Shen, Yanxiang Gao, Jingang Zheng

Published in: Cardiovascular Diabetology | Issue 1/2023

Login to get access

Abstract

Background

The triglyceride-glucose (TyG) index has been suggested as a dependable indicator for predicting major adverse cardiovascular events (MACE) in individuals with cardiovascular conditions. Nevertheless, there is insufficient data on the predictive significance of the TyG index in end-stage renal disease (ESRD) patients with coronary artery disease (CAD).

Methods

This study, conducted at multiple centers in China, included 959 patients diagnosed with dialysis and CAD from January 2015 to June 2021. Based on the TyG index, the participants were categorized into three distinct groups. The study’s primary endpoint was the combination of MACE occurring within one year of follow-up, including death from any cause, non-fatal myocardial infarction, and non-fatal stroke. We assessed the association between the TyG index and MACE using Cox proportional hazard models and restricted cubic spline analysis. The TyG index value was evaluated for prediction incrementally using C-statistics, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI).

Results

The three groups showed notable variations in the risk of MACE (16.3% in tertile 1, 23.5% in tertile 2, and 27.2% in tertile 3; log-rank P = 0.003). Following complete adjustment, patients with the highest TyG index exhibited a notably elevated risk of MACE in comparison to those in the lowest tertile (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.14–2.35, P = 0.007). Likewise, each unit increase in the TyG index correlated with a 1.37-fold higher risk of MACE (HR 1.37, 95% CI 1.13–1.66, P = 0.001). Restricted cubic spline analysis revealed a connection between the TyG index and MACE (P for nonlinearity > 0.05). Furthermore, incorporating the TyG index to the Global Registry of Acute Coronary Events risk score or baseline risk model with fully adjusted factors considerably enhanced the forecast of MACE, as demonstrated by the C-statistic, continuous NRI, and IDI.

Conclusions

The TyG index might serve as a valuable and dependable indicator of MACE risk in individuals with dialysis and CAD, indicating its potential significance in enhancing risk categorization in clinical settings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lai AC, Bienstock SW, Sharma R, Skorecki K, Beerkens F, Samtani R, et al. A personalized approach to chronic kidney disease and cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol. 2021;77:1470–9.PubMedCrossRef Lai AC, Bienstock SW, Sharma R, Skorecki K, Beerkens F, Samtani R, et al. A personalized approach to chronic kidney disease and cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol. 2021;77:1470–9.PubMedCrossRef
3.
go back to reference Limpijankit T, Chandavimol M, Srimahachota S, Kanoksilp A, Jianmongkol P, Siriyotha S, et al. Dose-dependent effect of impaired renal function on all-cause mortality in patients following percutaneous coronary intervention. Clin Cardiol. 2022;45:882–91.PubMedPubMedCentralCrossRef Limpijankit T, Chandavimol M, Srimahachota S, Kanoksilp A, Jianmongkol P, Siriyotha S, et al. Dose-dependent effect of impaired renal function on all-cause mortality in patients following percutaneous coronary intervention. Clin Cardiol. 2022;45:882–91.PubMedPubMedCentralCrossRef
4.
go back to reference Tobe A, Sawano M, Kohsaka S, Ishii H, Tanaka A, Numasawa Y, et al. Ischemic and bleeding outcomes in patients who underwent percutaneous coronary intervention with chronic kidney disease or dialysis (from a Japanese Nationwide Registry). Am J Cardiol. 2023;195:37–44.PubMedCrossRef Tobe A, Sawano M, Kohsaka S, Ishii H, Tanaka A, Numasawa Y, et al. Ischemic and bleeding outcomes in patients who underwent percutaneous coronary intervention with chronic kidney disease or dialysis (from a Japanese Nationwide Registry). Am J Cardiol. 2023;195:37–44.PubMedCrossRef
5.
6.
go back to reference Krediet RT, Balafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol. 2010;6:451–60.PubMedCrossRef Krediet RT, Balafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol. 2010;6:451–60.PubMedCrossRef
7.
go back to reference Bernardo AP, Oliveira JC, Santos O, Carvalho MJ, Cabrita A, Rodrigues A. Insulin resistance in nondiabetic peritoneal dialysis patients: associations with body composition, peritoneal transport, and peritoneal glucose absorption. Clin J Am Soc Nephrol. 2015;10:2205–12.PubMedPubMedCentralCrossRef Bernardo AP, Oliveira JC, Santos O, Carvalho MJ, Cabrita A, Rodrigues A. Insulin resistance in nondiabetic peritoneal dialysis patients: associations with body composition, peritoneal transport, and peritoneal glucose absorption. Clin J Am Soc Nephrol. 2015;10:2205–12.PubMedPubMedCentralCrossRef
8.
go back to reference Nishimura M, Tsukamoto K, Tamaki N, Kikuchi K, Iwamoto N, Ono T. Risk stratification for cardiac death in hemodialysis patients without obstructive coronary artery disease. Kidney Int. 2011;79:363–71.PubMedCrossRef Nishimura M, Tsukamoto K, Tamaki N, Kikuchi K, Iwamoto N, Ono T. Risk stratification for cardiac death in hemodialysis patients without obstructive coronary artery disease. Kidney Int. 2011;79:363–71.PubMedCrossRef
9.
go back to reference Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299–304.PubMedCrossRef Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299–304.PubMedCrossRef
10.
go back to reference Gastaldelli A. Measuring and estimating insulin resistance in clinical and research settings. Obesity (Silver Spring). 2022;30:1549–63.PubMedCrossRef Gastaldelli A. Measuring and estimating insulin resistance in clinical and research settings. Obesity (Silver Spring). 2022;30:1549–63.PubMedCrossRef
11.
go back to reference Mirjalili SR, Soltani S, Heidari Meybodi Z, Marques-Vidal P, Kraemer A, Sarebanhassanabadi M. An innovative model for predicting coronary heart disease using triglyceride-glucose index: a machine learning-based cohort study. Cardiovasc Diabetol. 2023;22:200.PubMedPubMedCentralCrossRef Mirjalili SR, Soltani S, Heidari Meybodi Z, Marques-Vidal P, Kraemer A, Sarebanhassanabadi M. An innovative model for predicting coronary heart disease using triglyceride-glucose index: a machine learning-based cohort study. Cardiovasc Diabetol. 2023;22:200.PubMedPubMedCentralCrossRef
12.
go back to reference Su J, Li Z, Huang M, Wang Y, Yang T, Ma M, et al. Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovasc Diabetol. 2022;21:96.PubMedPubMedCentralCrossRef Su J, Li Z, Huang M, Wang Y, Yang T, Ma M, et al. Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovasc Diabetol. 2022;21:96.PubMedPubMedCentralCrossRef
13.
go back to reference Park K, Ahn CW, Lee SB, Kang S, Nam JS, Lee BK, et al. Elevated TyG index predicts progression of coronary artery calcification. Diabetes Care. 2019;42:1569–73.PubMedCrossRef Park K, Ahn CW, Lee SB, Kang S, Nam JS, Lee BK, et al. Elevated TyG index predicts progression of coronary artery calcification. Diabetes Care. 2019;42:1569–73.PubMedCrossRef
14.
15.
go back to reference Baek J, He C, Afshinnia F, Michailidis G, Pennathur S. Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease. Nat Rev Nephrol. 2022;18:38.PubMedCrossRef Baek J, He C, Afshinnia F, Michailidis G, Pennathur S. Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease. Nat Rev Nephrol. 2022;18:38.PubMedCrossRef
16.
go back to reference Legouis D, Faivre A, Cippà PE, de Seigneux S. Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism. Nephrol Dial Transplant. 2022;37:1417–25.PubMedCrossRef Legouis D, Faivre A, Cippà PE, de Seigneux S. Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism. Nephrol Dial Transplant. 2022;37:1417–25.PubMedCrossRef
17.
go back to reference Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303.PubMedCrossRef Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303.PubMedCrossRef
18.
go back to reference Soohoo M, Moradi H, Obi Y, Kovesdy CP, Kalantar-Zadeh K, Streja E. Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. J Clin Lipidol. 2019;13:744–53.PubMedCrossRef Soohoo M, Moradi H, Obi Y, Kovesdy CP, Kalantar-Zadeh K, Streja E. Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. J Clin Lipidol. 2019;13:744–53.PubMedCrossRef
21.
go back to reference Hill CJ, Maxwell AP, Cardwell CR, Freedman BI, Tonelli M, Emoto M, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis. 2014;63:84–94.PubMedCrossRef Hill CJ, Maxwell AP, Cardwell CR, Freedman BI, Tonelli M, Emoto M, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis. 2014;63:84–94.PubMedCrossRef
22.
go back to reference Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345–53.PubMedCrossRef Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345–53.PubMedCrossRef
23.
go back to reference Alizargar J, Bai C-H, Hsieh N-C, Wu S-FV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol 2020;19:8. Alizargar J, Bai C-H, Hsieh N-C, Wu S-FV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol 2020;19:8.
24.
go back to reference Wu Z, Liu L, Wang W, Cui H, Zhang Y, Xu J, et al. Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study. Cardiovasc Diabetol. 2022;21:142.PubMedPubMedCentralCrossRef Wu Z, Liu L, Wang W, Cui H, Zhang Y, Xu J, et al. Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study. Cardiovasc Diabetol. 2022;21:142.PubMedPubMedCentralCrossRef
25.
go back to reference Jin J-L, Cao Y-X, Wu L-G, You X-D, Guo Y-L, Wu N-Q, et al. Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. J Thorac Dis. 2018;10:6137–46.PubMedPubMedCentralCrossRef Jin J-L, Cao Y-X, Wu L-G, You X-D, Guo Y-L, Wu N-Q, et al. Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. J Thorac Dis. 2018;10:6137–46.PubMedPubMedCentralCrossRef
26.
go back to reference Ye Z, An S, Gao Y, Xie E, Zhao X, Guo Z, et al. Association between the triglyceride glucose index and in-hospital and 1-year mortality in patients with chronic kidney disease and coronary artery disease in the intensive care unit. Cardiovasc Diabetol. 2023;22:110.PubMedPubMedCentralCrossRef Ye Z, An S, Gao Y, Xie E, Zhao X, Guo Z, et al. Association between the triglyceride glucose index and in-hospital and 1-year mortality in patients with chronic kidney disease and coronary artery disease in the intensive care unit. Cardiovasc Diabetol. 2023;22:110.PubMedPubMedCentralCrossRef
27.
go back to reference Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–82.PubMedCrossRef Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–82.PubMedCrossRef
28.
go back to reference Xiong S, Chen Q, Zhang Z, Chen Y, Hou J, Cui C, et al. A synergistic effect of the triglyceride-glucose index and the residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2022;21:115.PubMedPubMedCentralCrossRef Xiong S, Chen Q, Zhang Z, Chen Y, Hou J, Cui C, et al. A synergistic effect of the triglyceride-glucose index and the residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2022;21:115.PubMedPubMedCentralCrossRef
29.
go back to reference Radcliffe NJ, Seah J-M, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2017;8:6–18.PubMedCrossRef Radcliffe NJ, Seah J-M, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2017;8:6–18.PubMedCrossRef
30.
go back to reference Dave N, Wu J, Thomas S. Chronic kidney disease-induced insulin resistance: current state of the field. Curr Diab Rep. 2018;18:44.PubMedCrossRef Dave N, Wu J, Thomas S. Chronic kidney disease-induced insulin resistance: current state of the field. Curr Diab Rep. 2018;18:44.PubMedCrossRef
31.
go back to reference Nakashima A, Kato K, Ohkido I, Yokoo T. Role and treatment of insulin resistance in patients with chronic kidney disease: a review. Nutrients. 2021;13:56.CrossRef Nakashima A, Kato K, Ohkido I, Yokoo T. Role and treatment of insulin resistance in patients with chronic kidney disease: a review. Nutrients. 2021;13:56.CrossRef
32.
go back to reference Nishikawa T, Kukidome D, Sonoda K, Fujisawa K, Matsuhisa T, Motoshima H, et al. Impact of mitochondrial ROS production in the pathogenesis of insulin resistance. Diabetes Res Clin Pract. 2007;77(Suppl 1):S161-164.PubMedCrossRef Nishikawa T, Kukidome D, Sonoda K, Fujisawa K, Matsuhisa T, Motoshima H, et al. Impact of mitochondrial ROS production in the pathogenesis of insulin resistance. Diabetes Res Clin Pract. 2007;77(Suppl 1):S161-164.PubMedCrossRef
34.
go back to reference Tao L-C, Xu J, Wang T, Hua F, Li J-J. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21:68.PubMedPubMedCentralCrossRef Tao L-C, Xu J, Wang T, Hua F, Li J-J. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21:68.PubMedPubMedCentralCrossRef
35.
36.
go back to reference Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12:144–53.PubMedCrossRef Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12:144–53.PubMedCrossRef
37.
go back to reference Cho Y-R, Ann SH, Won K-B, Park G-M, Kim Y-G, Yang DH, et al. Association between insulin resistance, hyperglycemia, and coronary artery disease according to the presence of diabetes. Sci Rep. 2019;9:6129.PubMedPubMedCentralCrossRef Cho Y-R, Ann SH, Won K-B, Park G-M, Kim Y-G, Yang DH, et al. Association between insulin resistance, hyperglycemia, and coronary artery disease according to the presence of diabetes. Sci Rep. 2019;9:6129.PubMedPubMedCentralCrossRef
38.
go back to reference Zhang R, Shi S, Chen W, Wang Y, Lin X, Zhao Y, et al. Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database. Cardiovasc Diabetol. 2023;22:10.PubMedPubMedCentralCrossRef Zhang R, Shi S, Chen W, Wang Y, Lin X, Zhao Y, et al. Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database. Cardiovasc Diabetol. 2023;22:10.PubMedPubMedCentralCrossRef
39.
go back to reference Zhang Y, Ding X, Hua B, Liu Q, Gao H, Chen H, et al. High triglyceride-glucose index is associated with adverse cardiovascular outcomes in patients with acute myocardial infarction. Nutr Metab Cardiovasc Dis. 2020;30:2351–62.PubMedCrossRef Zhang Y, Ding X, Hua B, Liu Q, Gao H, Chen H, et al. High triglyceride-glucose index is associated with adverse cardiovascular outcomes in patients with acute myocardial infarction. Nutr Metab Cardiovasc Dis. 2020;30:2351–62.PubMedCrossRef
40.
go back to reference Zou S, Xu Y. Association of the triglyceride-glucose index and major adverse cardiac and cerebrovascular events in female patients undergoing percutaneous coronary intervention with drug-eluting stents: A retrospective study. Diabetes Res Clin Pract. 2021;181: 109073.PubMedCrossRef Zou S, Xu Y. Association of the triglyceride-glucose index and major adverse cardiac and cerebrovascular events in female patients undergoing percutaneous coronary intervention with drug-eluting stents: A retrospective study. Diabetes Res Clin Pract. 2021;181: 109073.PubMedCrossRef
41.
go back to reference Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e21-129.PubMedCrossRef Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e21-129.PubMedCrossRef
42.
go back to reference Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–367.PubMedCrossRef Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–367.PubMedCrossRef
43.
go back to reference Gurm HS, Gore JM, Anderson FAJ, Wyman A, Fox KAA, Steg PG, et al. Comparison of acute coronary syndrome in patients receiving versus not receiving chronic dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). Am J Cardiol. 2012;109:19–25.PubMedCrossRef Gurm HS, Gore JM, Anderson FAJ, Wyman A, Fox KAA, Steg PG, et al. Comparison of acute coronary syndrome in patients receiving versus not receiving chronic dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). Am J Cardiol. 2012;109:19–25.PubMedCrossRef
44.
go back to reference Xiong S, Chen Q, Chen X, Hou J, Chen Y, Long Y, et al. Adjustment of the GRACE score by the triglyceride glucose index improves the prediction of clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2022;21:145.PubMedPubMedCentralCrossRef Xiong S, Chen Q, Chen X, Hou J, Chen Y, Long Y, et al. Adjustment of the GRACE score by the triglyceride glucose index improves the prediction of clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2022;21:145.PubMedPubMedCentralCrossRef
Metadata
Title
The triglyceride-glucose index predicts 1-year major adverse cardiovascular events in end-stage renal disease patients with coronary artery disease
Authors
Enmin Xie
Zixiang Ye
Yaxin Wu
Xuecheng Zhao
Yike Li
Nan Shen
Yanxiang Gao
Jingang Zheng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-023-02028-7

Other articles of this Issue 1/2023

Cardiovascular Diabetology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.